The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Comparison of ciprofloxacin hydrochloride‐loaded protein, lipid, and chitosan nanoparticles for drug delivery
Abstract
The aim of the present study was to develop single dose delivery systems based on nanotechnology for prolonged antibiotic release in a controlled manner. Five different drug–carrier ratios of ciprofloxacin hydrochloride‐loaded nanoparticles of albumin, gelatin, chitosan (CS), and lipid [solid lipid nanoparticles (SLNs)] were prepared and characterized. Average particle size was found to be in the range of 73 ± 2 to 98 ± 44 nm for SLNs, 140 ± 7 to 175 ± 24 nm for albumin nanoparticles, 143 ± 18 to 184 ± 27 nm for gelatin nanoparticles, and 247 ± 48 to 322 ± 52 nm for CS nanoparticles. A drug‐to‐carrier ratio of 0.5:1 was preferred for CS nanoparticles having zeta potential of >20 mV and drug encapsulation of 35.01% ± 2.66%. Similarly, 0.6:1 ratio was preferred for albumin nanoparticles with zeta potential >16 mV and drug encapsulation 48.20% ± 3.01%. Zeta potentials of gelatin nanoparticles loaded with ciprofloxacin suggested that they were unstable and prone to flocculation. SLN with 0.25:1 drug carrier ratio showed 38.71% ± 2.38% drug entrapment and −28 ± 1 mV surface charge. All the nanoparticles showed sustained drug release avoiding “burst effect” of the free drugs for up to 120 h for albumin nanoparticles, 96 h for CS and gelatin nanoparticles, and 80 h for SLNs. The drug release profiles followed Higuchi model. Results suggest that CS nanoparticles and SLNs can act as promising carriers for sustained ciprofloxacin release in infective conditions. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2008
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jain et al. used different nanocarriers for ciprofloxacin encapsulation and showed that SLNs were able to promote a prolonged drug release.215”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [215]
In the citing paper
“Apart from ciprofloxacin, SLNs were also capable of loading other anti-TB drugs, such as rifabutin, INH, RIF, and PZA.215”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [215]
In the citing paper
“Jain and Banerjee also demonstrated the sustained release of ciprofloxacin (up to 80 h).215”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [215]
In the citing paper
“SLNs have been extensively used in formulations for the delivery of anti-TB drugs.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [215]
Citations
Cites
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,494
Optimization of the preparation process for human serum albumin (HSA) nanoparticles
Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., & Schubert, D. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00134-0 · Cited by 760
Desolvation process and surface characterisation of protein nanoparticles
Weber, C., Coester, C., Kreuter, J., & Langer, K. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00370-1 · Cited by 605
Schwarz, C., Mehnert, W., Lucks, J. S., & Müller, R. H. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90047-7 · Cited by 574
Preparation and characterization of chitosan microparticles intended for controlled drug delivery
Ko, J. A., Park, H. J., Hwang, S., Park, J. B., & Lee, J. S. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00487-8 · Cited by 462
Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles
Banerjee, T., Mitra, S., Singh, A. K., Sharma, R. K., & Maitra, A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00267-3 · Cited by 409
Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration
Wissing, S. A., & Müller, R. H. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00056-1 · Cited by 405
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin
Cavalli, R., Gasco, M. R., Chetoni, P., Burgalassi, S., & Saettone, M. F. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00080-7 · Cited by 389
Roser, M., Fischer, D., & Kissel, T. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(98)00038-1 · Cited by 368
Nanomedicines for overcoming biological barriers
Alonso, M. J. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.01.007 · Cited by 312
Oral solid lipid nanoparticle-based antitubercular chemotherapy
Pandey, R., Sharma, S., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.08.009 · Cited by 271
Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use
Vandervoort, J., & Ludwig, A. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(03)00187-5 · Cited by 247
Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties
Merodio, M., Arnedo, A., Renedo, M. J., & Irache, J. M. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00169-x · Cited by 235
Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles
Dillen, K., Vandervoort, J., den Mooter, G. V., & Ludwig, A. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.01.041 · Cited by 230
Olivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213
Formulation pH modulates the interaction of insulin with chitosan nanoparticles
Ma, Z., Yeoh, H. H., & Lim, L. Y. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10149 · Cited by 199
Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles
Dillen, K., Vandervoort, J., den Mooter, G. V., Verheyden, L., & Ludwig, A. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.01.033 · Cited by 175
Lherm, C., Müller, R. H., Puisieux, F., & Couvreur, P. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90210-s · Cited by 159
Physicochemical properties and blood compatibility of acylated chitosan nanoparticles
Lee, D. A., Powers, K. W., & Baney, R. H. (2004) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2004.06.033 · Cited by 154
In vitro toxicity test of 2‐cyanoacrylate polymers by cell culture method
Tseng, Y., Tabata, Y., Hyon, S., & Ikada, Y. (1990) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820241007 · Cited by 143
Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor
Aktaş, Y., Andrieux, K., Alonso, M. J., Calvo, P., Gürsoy, R. N., Couvreur, P., & Çapan, Y. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.027 · Cited by 135
Merodio, M., Irache, J. M., Valamanesh, F., & Mirshahi, M. (2002) · Biomaterials · doi:10.1016/s0142-9612(01)00284-8 · Cited by 132
Essentials of Medical Pharmacology
Codi, R. S. (2018) · SBV Journal of Basic Clinical and Applied Health Science · doi:10.5005/jp-journals-10082-01142 · Cited by 104
Song, C., & Liu, S. (2005) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2005.05.003 · Cited by 92
Effervescent dry powder for respiratory drug delivery
Ely, L., Roa, W., Finlay, W. H., & Löbenberg, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.10.021 · Cited by 86
Albumin microspheres as carriers for the antiarthritic drug celecoxib
Thakkar, H. P., Sharma, R. K., Mishra, A. K., Chuttani, K., & Murthy, R. (2005) · AAPS PharmSciTech · doi:10.1208/pt060112 · Cited by 78
Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier
Page-Clisson, M.-E., Pinto‐Alphandary, H., Ourévitch, M., Andremont, A., & Couvreur, P. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00065-0 · Cited by 74
Lister, P., & Sanders, C. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1118 · Cited by 73
Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous
Yalvaç, I. S., Başcı, N. E., Bozkurt, A., & Duman, S. (2003) · Journal of Cataract & Refractive Surgery · doi:10.1016/s0886-3350(02)01538-9 · Cited by 61
Trapani, G., Franco, M., Latrofa, A., Pantaleo, M. R., Provenzano, M. R., Sanna, E., Maciocco, E., & Liso, G. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00112-x · Cited by 56
Fawaz, F., Bonini, F., Maugein, J., & Lagueny, A. M. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00116-1 · Cited by 49
Bhavane, R. C., Karathanasis, E., & Annapragada, A. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00359-6 · Cited by 46
Optimization of propranolol hydrochloride sustained release pellets using a factorial design
Bodea, A., & Leucuta, S. E. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00114-2 · Cited by 41
Lipsky, B. A., Miller, B. H., Schwartz, R. A., Henry, D. C., Nolan, T., McCabe, A. M., Magner, D. J., & Talbot, G. H. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88319-8 · Cited by 29
Research works printed but not linked: 2
- Coester C, 2006, In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localization, Eur J Pharm Sci, 62, 306
- Utreja S, 2001, Advances in Controlled and Novel Drug Delivery, 408
Cited by
Sorted by citations
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,920
Polysaccharides-based nanoparticles as drug delivery systems
Liu, Z., Jiao, Y., Wang, Y., Zhou, C., & Zhang, Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.001 · Cited by 1,739
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,526
Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research
Elzoghby, A. O. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.019 · Cited by 657
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Metadata
- Authors
- Jain, D., & Banerjee, R.
- Affiliations
- Indian Institute of Technology Bombay (IN)
- Corresponding author
- Banerjee, R.
- Venue
- Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Publisher
- Wiley
- Published
- 2007-12-20
- Volume
- 86B
- Issue
- 1
- Pages
- 105-112
- ISSN
- 1552-4973 (ISSN-L)
- 1552-4981
- OpenAlex
- W2074420216
- Cited by
- 158
- References
- 34
- Citations by year
- 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 14 · 2020: 11 · 2019: 15 · 2018: 12 · 2017: 18 · 2016: 15 · 2015: 7 · 2014: 5 · 2013: 11 · 2012: 4
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Biomedical Materials Research Part B Applied Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- DSpace (IIT Bombay) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- ciprofloxacin hydrochloride, chitosan nanoparticles, solid lipid nanoparticles, albumin nanoparticles, gelatin nanoparticles, sustained drug release, encapsulation efficiency, zeta potential, Higuchi model, burst release, nanoparticle stability
- MeSH terms
- Albumins, Animals, Cattle, Ciprofloxacin, Drug Carriers, Gelatin, Lipids, Particle Size, Polymers, Scattering, Radiation, Serum Albumin, Drug Delivery Systems, Nanotechnology, Chitosan, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
